絞り込み

16545

広告

1083件中 181件~200件表示    検索結果をPubMedで見る PubMedで見る

Cost-effectiveness analysis of policy options on first-line treatments for advanced, non-small cell lung cancer in Thailand.

Effectiveness of afatinib after ineffectiveness of gefitinib in an advanced lung adenocarcinoma patient with a single EGFR exon 20 S768I mutation: a case report.

Application of molecular targeted therapies in the treatment of head and neck squamous cell carcinoma.

Isolated metastasis of an EGFR-L858R-mutated NSCLC of the meninges: the potential impact of CXCL12/CXCR4 axis in EGFR NSCLC in diagnosis, follow-up and treatment.

Transformation to small cell lung cancer after first-line afatinib treatment.

Acquired T790M Mutation After Relapse Following EGFR-TKI Therapy: A Population-based Multi-institutional Study.

Tyrosine Kinase Inhibition in HPV-related Squamous Cell Carcinoma Reveals Beneficial Expression of cKIT and Src.

Sleeve lobectomy for lung adenocarcinoma treated with neoadjuvant afatinib.

Afatinib in Osimertinib-Resistant EGFR ex19del / T790M / P794L mutated Non-Small Cell Lung Cancer.

Identification of mutation accumulation as resistance mechanism emerging in first-line osimertinib treatment.

Brief report: Afatinib and cetuximab in four patients with EGFR exon 20 insertion positive advanced non-small-cell lung cancer.

Medical Treatment Options for Patients with Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer Suffering from Brain Metastases and/or Leptomeningeal Disease.

Higher expression of miR-133b is associated with better efficacy of erlotinib as the second or third line in non-small cell lung cancer patients.

Molecular mechanism of action and potential biomarkers of growth inhibition of synergistic combination of afatinib and dasatinib against gefitinib-resistant non-small cell lung cancer cells.

Quantitative targeted proteomic analysis of potential markers of tyrosine kinase inhibitor (TKI) sensitivity in EGFR mutated lung adenocarcinoma.

Afatinib in heavily pretreated advanced NSCLC patients who progressed following prior gefitinib or erlotinib: Compassionate use program in Korea.

Afatinib as First-line Treatment of Older Patients With EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Subgroup Analyses of the LUX-Lung 3, LUX-Lung 6, and LUX-Lung 7 Trials.

Osimertinib: A Novel Dermatologic Adverse Event Profile in Patients with Lung Cancer.

Lung adenocarcinoma presenting as intramedullary spinal cord metastasis: Case report and review of literature.

Response to ERBB3-Directed Targeted Therapy in NRG1-Rearranged Cancers.

  1. 6
  2. 7
  3. 8
  4. 9
  5. 10
  6. 11
  7. 12
  8. 13
  9. 14
  10. 15
Sort by
※並べ替えは表示に時間がかかります